Onco
Emerging Drug Developers Developing Cancer Targeting Exosomes
Exosomes are cell-derived nanovesicles, which are usually 50-150 nm in diameter and are involved in the intercellular transportation of materials....
Cancer Microbiome Targeting Emerging Drug Developers
Microbiome is an emerging player in cancer drug development. Recent research findings elicit varied roles of human gut microbiome, both...
Antibody Drug Conjugates
Antibody Drug Conjugates (ADCs) are therapeutic entities with monoclonal antibody (mAb) backbone linked to cytotoxic drugs and are designed to...
Oncolytic Viruses
Oncolytic Viruses (OVs) based therapies uses natural or genetically modified viruses to specifically infect and lyse cancer cells but does not...
Bispecific Antibodies
Bispecific (bsAbs) & Multispecific antibodies are a diverse family of antibody constructs that recognize two or more epitopes. These candidates...
Cancer Targeting Cellular Therapies
Cell Therapies constitutes the largest number of agents in oncology drug development, with currently more than 2000+ Active Cancer Targeting...
Onco
Emerging Drug Developers Developing Cancer Targeting Exosomes
Exosomes are cell-derived nanovesicles, which are usually 50-150 nm in diameter and are involved in the intercellular transportation of materials....
Cancer Microbiome Targeting Emerging Drug Developers
Microbiome is an emerging player in cancer drug development. Recent research findings elicit varied roles of human gut microbiome, both...
Antibody Drug Conjugates
Antibody Drug Conjugates (ADCs) are therapeutic entities with monoclonal antibody (mAb) backbone linked to cytotoxic drugs and are designed to...
Oncolytic Viruses
Oncolytic Viruses (OVs) based therapies uses natural or genetically modified viruses to specifically infect and lyse cancer cells but does not...
Bispecific Antibodies
Bispecific (bsAbs) & Multispecific antibodies are a diverse family of antibody constructs that recognize two or more epitopes. These candidates...
Cancer Targeting Cellular Therapies
Cell Therapies constitutes the largest number of agents in oncology drug development, with currently more than 2000+ Active Cancer Targeting...
